A strain of Weizmannella coagulans VB320 against Helicobacter pylori and its application and culture device

By using Weizmannia coagulated VB320 and its fermentation broth or bacterial suspension, the intestinal flora is regulated, and the antibiotic resistance and side effects of Helicobacter pylori treatment in the prior art has been solved, achieving efficient and safe treatment Effect.

CN118562689BActive Publication Date: 2024-11-22HANGZHOU VICROBX BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411063713.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-22
Estimated Expiration
2044-08-05

AI Technical Summary

Technical Problem

The existing Helicobacter pylori treatment methods have shortcomings such as antibiotic resistance, long culture time, high cost, and unknown side effects, and the effect and standardization of probiotic therapy are not high.

Method used

Using Weizmannia coagulated VB320 and its fermentation broth or bacterial suspension, regulates the intestinal flora through its strong antibacterial ability and gastrointestinal tolerance, prevents and treats diseases caused by pathogenic bacteria, and avoids antibiotic resistance. The creation of sex.

Benefits of technology

Effectively inhibit the growth of pathogens, improve the success rate of treatment of Helicobacter pylori, reduce side effects, and do not lead to the occurrence of antibiotic resistance, providing a safe and effective treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118562689B_ABST
    Figure CN118562689B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of microorganisms, and specifically proposes a strain of Weizmannella coagulans VB320 that resists Helicobacter pylori, and its application and culture device. The Weizmannella coagulans VB320 was deposited in the China Center for Type Culture Collection on April 3, 2024, and the deposit number is CCTCC No: M 2024626. The Weizmannella coagulans VB320 of the present invention has the advantages of strong antibacterial ability and strong gastrointestinal tolerance, has strong antibacterial ability for common pathogens, and does not cause drug resistance, can be used to regulate intestinal flora, prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection, and has high application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of microorganisms, and in particular to a strain of Weizmannella coagulans VB320 resistant to Helicobacter pylori and an application and a culture device thereof. Background Art

[0002] Various studies have shown that Helicobacter pylori is a Gram-negative bacillus that is the culprit of gastric diseases. It colonizes in the gastric epithelium, causing persistent or lifelong infection. It infects a large number of people worldwide, posing a significant threat to public health. This pathogen is not only associated with the incidence of peptic ulcers, functional dyspepsia, and gastric mucosa-associated lymphoma, but is also one of the important causes of gastric cancer. In addition, it may also be associated with coronary heart disease, hypertension, unexplained thrombocytopenic purpura, iron deficiency anemia, rosacea and other diseases. Therefore, once Helicobacter pylori is detected to be positive, timely treatment is crucial. Infected gastric patients often show painful symptoms such as digestive discomfort, belching, abdominal distension and pain, acid reflux, and even decreased gastric blood flow, which seriously affect the quality of life and health.

[0003] At present, the methods for treating Helicobacter pylori include traditional bismuth quadruple therapy, HP in vitro drug sensitivity culture, potassium competitive acid blockers, traditional Chinese medicine, probiotics, etc. Bismuth quadruple therapy has the problem that HP has an increasing resistance to antibiotics due to the abuse of antibiotics, and the eradication rate is also gradually declining. Drug sensitivity culture has the disadvantages of long culture time, easy contamination of specimens and high price. In addition, due to the difference between in vivo and in vitro, in refractory Helicobacter pylori, the success rate of drug sensitivity culture is 79% to 90%, and the success rate of eradication is between 36% and 90%. Potassium competitive acid blockers (P-CABs) are mainly studied in Japan, and there are few reports on adverse reactions. They also need to be combined with amoxicillin + clarithromycin. Not only does it require multi-center and large sample verification, but it also cannot solve the problem of antibiotic resistance. Traditional Chinese medicine therapy has problems such as slow effect, unclear quality and standardization, poor taste, unclear interactions and toxic side effects.

[0004] Weizmannii coagulans is the current research focus. It is a strain that can both form spores and produce lactic acid, and has attracted much attention in the field of probiotics. It can produce abundant beneficial metabolites, such as coagulins and short-chain fatty acids, which help inhibit common intestinal harmful bacteria such as Escherichia coli and Salmonella. In addition, because of its ability to form spores with a strong protective layer, it can still maintain its viability in the face of strong acids, high bile salt concentrations, and extreme temperatures and pressures. Therefore, after entering the human body, it is more likely to survive and play a more effective probiotic function.

[0005] Therefore, probiotic therapy, as a new treatment method that neither causes other side effects nor increases the drug resistance of Helicobacter pylori, is worthy of research and attention. Summary of the invention

[0006] The present invention aims to solve at least one of the technical problems existing in the prior art to at least a certain extent.

[0007] To this end, in a first aspect of the present invention, the present invention provides a coagulant Weizmannella (Weizmannia coagulans VB320. According to an embodiment of the present invention, the Weizmannella coagulans VB320 was deposited in the China Center for Type Culture Collection on April 3, 2024, with a deposit number of CCTCC No: M 2024626.

[0008] The Weizmannella coagulans VB320 screened by the present invention has the advantages of strong antibacterial ability, strong gastrointestinal tolerance, etc. It has strong antibacterial ability against common pathogens and will not cause drug resistance. It can be used to regulate intestinal flora, prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection, and has high application value.

[0009] In a second aspect of the present invention, the present invention provides a fermentation broth. According to an embodiment of the present invention, the fermentation broth is fermented by the Weizmannella coagulans VB320 described in the first aspect. The fermentation broth of the present invention can be used to regulate intestinal flora, and can also be used to prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0010] In the third aspect of the present invention, the present invention provides a bacterial suspension. According to an embodiment of the present invention, the bacterial suspension includes the Weizmannella coagulans VB320 described in the first aspect. The bacterial suspension of the present invention can be used to regulate intestinal flora, and can also be used to prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0011] In the fourth aspect of the present invention, the present invention proposes the use of the Weizmannella coagulans VB320 described in the first aspect, the fermentation broth described in the second aspect, or the bacterial suspension described in the third aspect in the preparation of a medicine or feed for inhibiting the activity of pathogenic bacteria. The feed of the present invention can be used to regulate intestinal flora, and the medicine of the present invention can be used to regulate intestinal flora, prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0012] In the fifth aspect of the present invention, the present invention provides a composition. According to an embodiment of the present invention, the composition comprises at least one of the Weizmannella coagulans VB320 described in the first aspect, the fermentation broth described in the second aspect, and the bacterial suspension described in the third aspect. The composition of the present invention can be used to regulate intestinal flora, prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0013] In a sixth aspect of the present invention, the present invention provides a method for inhibiting the growth of pathogenic bacteria in vitro. According to an embodiment of the present invention, the method comprises: co-culturing at least one of the Weizmannella coagulans VB320 described in the first aspect, the fermentation broth described in the second aspect, and the bacterial suspension described in the third aspect with pathogenic bacteria. As mentioned above, the Weizmannella coagulans VB320 of the present invention can effectively inhibit the growth of pathogenic bacteria.

[0014] In the seventh aspect of the present invention, the present invention provides a culture device or a production device for the Weizmannella coagulans VB320 described in the first aspect, the fermentation broth described in the second aspect, the bacterial suspension described in the third aspect, or the composition described in the fifth aspect. The culture device or the production device according to the embodiment of the present invention can mass-produce the Weizmannella coagulans VB320, the fermentation broth, the bacterial suspension, or the composition described in the present invention.

[0015] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0017] Figure 1 This is a graph showing the test results of the tolerance of artificial simulated gastric juice of Weizmannella coagulans VB320 according to Example 2 of the present invention;

[0018] Figure 2 This is a graph showing the test results of the tolerance of Weizmannella coagulans VB320 to artificial simulated intestinal fluid according to Example 2 of the present invention;

[0019] Figure 3 This is a graph showing the test result of the tolerance of artificial simulated pancreatic juice of Weizmannella coagulans VB320 according to Example 2 of the present invention;

[0020] Figure 4 This is a scanning electron microscope result of the coagulation of Weizmannella VB320 according to Example 1 of the present invention. DETAILED DESCRIPTION

[0021] Embodiments of the present invention are described in detail below, and examples of the embodiments are shown in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are exemplary and intended to be used to explain the present invention, but should not be understood as limiting the present invention.

[0022] In addition, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include at least one of the features. In the description of the present invention, the meaning of "plurality" and "multiple" is at least two or two, such as two, two, three, three, etc., unless otherwise clearly and specifically defined.

[0023] In this document, the terms “include”, “have” or “comprises” are open expressions, that is, they include the contents specified in the present invention but do not exclude other contents.

[0024] As used herein, the term "optionally" generally means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0025] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0026] In order to make the present invention more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present invention belongs.

[0027] As used herein, the terms "treatment" and "alleviation" both refer to the use of drugs to obtain the desired pharmacological and / or physiological effects. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or may be therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, especially humans, including: (a) preventing the occurrence of a disease or condition in an individual who is susceptible to the disease but has not yet been diagnosed with the disease; (b) inhibiting the disease, such as blocking the progression of the disease; or (c) alleviating the disease, such as alleviating symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a strain, fermentation broth, bacterial suspension or composition to an individual to treat, cure, alleviate, improve, reduce or inhibit the individual's disease, including but not limited to administering a strain, fermentation broth, bacterial suspension or composition described herein to an individual in need.

[0028] As used herein, the term "carrier" includes any solvent, drug stabilizer, or combination thereof, which are known to those skilled in the art. Except where any conventional carrier is incompatible with the active ingredient, its use in treatment or pharmaceutical compositions is contemplated.

[0029] strain

[0030] In some embodiments, the present invention provides a Weizmannella coagulans (Weizmannia coagulans) VB320, the coagulant Weizmannella VB320 was deposited in the China Center for Type Culture Collection on April 3, 2024, with the deposit number CGMCC M 2024626.

[0031] According to some specific embodiments of the present invention, the coagulant Weizmannella VB320 may further include at least one of the following additional technical features:

[0032] According to some specific embodiments of the present invention, the Weizmannella coagulans VB320 has a 16S rRNA sequence as shown in SEQ ID NO:1.

[0033] The coagulant Weizmannella obtained by screening of the present invention (Weizmannia coagulans) The new strain VB320 has the advantages of strong antibacterial ability and strong gastrointestinal tolerance. It has strong antibacterial ability against common pathogens and will not cause drug resistance. It can be used to regulate intestinal flora, prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection, and has high application value.

[0034] In this document, the term “Weizmannella coagulans (Weizmannia coagulans) VB320", "Weizmannella coagulans VB320", "VB320 strain" and "VB320" are synonymous.

[0035] Fermentation Broth

[0036] In some embodiments, the present invention provides a fermentation broth, which is fermented by the aforementioned Weizmannella coagulans VB320. The fermentation broth of the present invention can be used to regulate intestinal flora, and can also be used to prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0037] It should be noted that the "fermentation broth" of the present invention refers to the solution obtained after culturing Weizmannella coagulans VB320 for a period of time, which solution mainly contains Weizmannella coagulans VB320 and its metabolites; or the supernatant after further treatment by centrifugation, filtration and other means, which supernatant mainly contains the metabolites of Weizmannella coagulans VB320.

[0038] bacterial suspension

[0039] In some embodiments, the present invention provides a bacterial suspension, which includes the aforementioned Weizmannella coagulans VB320. The bacterial suspension of the present invention can be used to regulate intestinal flora, and can also be used to prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0040] It should be noted that the bacterial suspension can be obtained by treating the above fermentation broth by means of centrifugation, resuspension, etc.

[0041] use

[0042] In some embodiments, the present invention provides the use of the aforementioned Weizmannella coagulans VB320, fermentation broth or bacterial suspension in the preparation of a medicine or feed for inhibiting the activity of pathogenic bacteria. The feed of the present invention can be used to regulate intestinal flora, and the medicine of the present invention can be used to regulate intestinal flora, prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0043] According to an embodiment of the present invention, the above-mentioned use may further include at least one of the following additional technical features:

[0044] According to an embodiment of the present invention, the pathogenic bacteria include Helicobacter pylori.

[0045] According to an embodiment of the present invention, the pathogenic bacteria further include at least one of Listeria monocytogenes, Enterococcus faecalis, Staphylococcus aureus, Salmonella, Shigella and Clostridium perfringens.

[0046] Medicine or feed

[0047] The present invention provides a medicine or feed, which comprises at least one of the aforementioned Weizmannella coagulans VB320, fermentation broth or bacterial suspension. The feed of the present invention can be used to regulate intestinal flora, and the medicine of the present invention can be used to regulate intestinal flora, prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0048] According to an embodiment of the present invention, the above-mentioned medicine or feed may further include at least one of the following additional technical features:

[0049] According to an embodiment of the present invention, it further comprises a pharmaceutically acceptable excipient or carrier or an excipient or carrier acceptable in animal feed.

[0050] In this article, "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammals treated therewith. Preferably, "pharmaceutically acceptable" as described in the present invention refers to those approved by federal regulatory agencies or national governments or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopeias for use in animals, particularly humans.

[0051] In this context, "adjuvant or carrier acceptable in animal feed" refers to a substance or composition that can be consumed by animals, which may be adjusted according to the animal feed requirements of different countries.

[0052] As used herein, the term "pharmaceutically acceptable carrier" includes any solvent, drug stabilizer, or combination thereof, which are known to those skilled in the art. Except where any conventional carrier is incompatible with the active ingredient, its use in treatment or pharmaceutical compositions is covered.

[0053] As used herein, the term "pharmaceutically acceptable excipient" may include any solvent suitable for a particular target dosage form. Except to the extent that any conventional excipient is incompatible with the Weizmannella coagulans VB320 disclosed herein, such as any adverse biological effects produced or interactions with any other components of the pharmaceutically acceptable composition in a deleterious manner, their use is also contemplated by the present disclosure.

[0054] According to an embodiment of the present invention, at least one of the aforementioned Weizmannella coagulans VB320, fermentation broth and bacterial suspension is added or inoculated into feed or added to medicine, thereby further obtaining feed with the function of regulating intestinal flora, or obtaining medicines that can prevent, alleviate and / or treat pathogenic bacteria infections or diseases caused by pathogenic bacteria infections.

[0055] For example, the aforementioned medicines include but are not limited to: medicines for human use and medicines for animals. The aforementioned medicines for animals may be for pets, livestock, or wild animals.

[0056] It should be noted that the characteristics and advantages described above for Weizmannella coagulans VB320 are also applicable to the medicine or feed and will not be repeated here.

[0057] Composition

[0058] In some embodiments, the present invention provides a composition, which comprises at least one of the aforementioned Weizmannella coagulans VB320, fermentation broth and bacterial suspension. The composition of the present invention can be used to regulate intestinal flora, prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0059] According to an embodiment of the present invention, the above composition may further include at least one of the following additional technical features:

[0060] According to an embodiment of the present invention, the composition further comprises an ingestible excipient and / or carrier.

[0061] According to an embodiment of the present invention, the excipient includes at least one selected from a binder, a disintegrant, a lubricant, a glidant, a stabilizer, a filler, a diluent and a sustained-release agent.

[0062] According to an embodiment of the present invention, the carrier includes at least one selected from sugars, cellulose and its derivatives, calcium phosphates, alkaline earth metal stearates, vegetable oils, nonionic surfactants, cationic surfactants, anionic surfactants, fatty alcohols and cereal hydrolyzed solids.

[0063] According to an embodiment of the present invention, the dosage form of the composition includes at least one selected from oral liquid, powder, granule, capsule, tablet, and pill.

[0064] method

[0065] In some embodiments, the present invention provides a method for inhibiting the growth of pathogenic bacteria in vitro, the method comprising: co-culturing the pathogenic bacteria with at least one of the aforementioned Weizmannella coagulans VB320, fermentation broth and bacterial suspension. As mentioned above, the Weizmannella coagulans VB320 of the present invention can effectively inhibit the growth of pathogenic bacteria.

[0066] According to an embodiment of the present invention, the above method may further include at least one of the following additional technical features:

[0067] According to an embodiment of the present invention, the pathogenic bacteria include Helicobacter pylori.

[0068] According to an embodiment of the present invention, the pathogenic bacteria further include at least one of Listeria monocytogenes, Enterococcus faecalis, Staphylococcus aureus, Salmonella, Shigella and Clostridium perfringens.

[0069] Device

[0070] In some embodiments, the present invention provides a culture device or production device for the aforementioned Weizmannella coagulans VB320, fermentation broth, bacterial suspension or composition. The culture device or production device according to the embodiment of the present invention can realize mass production of the Weizmannella coagulans VB320, fermentation broth, bacterial suspension or composition of the present invention, such as: culture dishes, culture bottles, fermentation tanks, shaking incubators, incubators, bioreactors, microfluidic chips (for miniaturized cultivation of microorganisms), etc. The above devices can be used alone or in combination, and the most suitable equipment can be selected according to the characteristics of the product to be cultured or produced, the production scale and the requirements of the production process.

[0071] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.

[0072] Example 1 Identification of Weizmannella coagulans strains

[0073] (1) Source of strains

[0074] The coagulant Weizmannella VB320 used in this application was isolated from condensed milk. Take unopened homemade condensed milk from a farm in Inner Mongolia, add sterile PBS buffer in a sterile container, shake it thoroughly, dilute and spread it on an MRS agar medium (purchased from BD Biosciences, item number 288210), and culture it in an anaerobic environment at 37°C for 48 hours. Pick out single colonies of different sizes and shapes and streak them on a fresh plate, then pick out single colonies and examine the colony morphology under a microscope. After no foreign bacteria are found under a microscope, identify them and take electron microscope photos. The obtained photos are as shown in the figure. Figure 4 shown.

[0075] (2) Strain identification

[0076] The experiment was conducted according to the relevant contents in the Molecular Cloning Experiment Guide. After the purified single strain was cultured in MRS liquid medium for 1 day, 1 mL of bacterial liquid was centrifuged at 10,000 rpm for 1 min, the supernatant was discarded, and the bacteria were collected. DNA was extracted according to the operation steps of MAGEN Bacterial Genomic DNA Extraction Kit (purchased from Shanghai Maigen Biotechnology Co., Ltd.). The extracted DNA was used as a template, and 16S rRNA was amplified by PCR (polymerase chain reaction) using universal primers 337F (5'-GACTCCTACGGGAGGCWGCAG-3') and 1492R (5'-TACGGCTACCTTGTTACGACTT-3'). The PCR reaction system was 50 μL, and the reaction system and program were configured according to the instructions of Phusion High-Fidelity DNA Polymerase (purchased from Thermo Scientific), and the annealing temperature was 55°C. The obtained PCR products were sequenced (Shanghai Sangon Biotechnology Co., Ltd.).

[0077] The 16S rRNA sequence of the strain was proofread and then compared with the sequences of related species and genera in the GenBank database by BLAST to determine the taxonomic status of the strain.

[0078] After comparison, it was found that the bacteria had a homology of up to 99% with Heyndrickxia coagulans strain 2382 and 99% with Heyndrickxia coagulans strain 4552, so the strain was identified as Heyndrickxia coagulans strain. The internal number of this strain is VB320, and it was deposited in the China Center for Type Culture Collection on April 3, 2024, with the deposit number CGMCC M 2024626.

[0079] The 16S rRNA sequencing result of Weizmannella coagulans VB320 is shown in SEQ ID NO: 1:

[0080]

[0081] Example 2 Evaluation of the ability of coagulating Weizmannella to tolerate the gastrointestinal tract

[0082] Preparation of artificial simulated gastric fluid: 1% sodium chloride solution with pH values ​​of 2.0, 2.5, 3, 4, 5, and 7 was prepared respectively, sterilized at 121°C for 30 min, and pepsin was added at 0.3%;

[0083] Artificial intestinal fluid: R22156-500 mL, purchased from Shanghai Yuanye Biotechnology;

[0084] Preparation of artificial simulated pancreatic juice: first prepare a 1% sodium chloride solution, then add tadalafil at concentrations of 0, 0.033%, 0.066%, 0.11%, 0.22%, and 0.33%, respectively, sterilize at 121°C for 30 min, and then add trypsin at a concentration of 0.1%.

[0085] Preparation of bacterial suspension: Take the counted Weizmannella coagulans VB320 bacterial suspension (the viable count should reach about 10 9 -10 10 CFU / mL), and after thawing, added into the above-mentioned artificial simulated gastric juice, intestinal juice and pancreatic juice respectively, the added amount was 10 μL bacterial suspension + 990 μL artificial simulated liquid, mixed, and cultured anaerobically at 37°C, and the live bacteria were counted at 0 h, 2 h, 3 h, and 4 h for the above-mentioned simulated gastric juice, at 0 h, 2 h, 4 h, 6 h, and 8 h for the above-mentioned simulated intestinal juice, and at 0 h, 1 h, 2 h, 3 h, 4 h, and 5 h for the above-mentioned simulated pancreatic juice, and the bacterial survival rates were calculated respectively.

[0086] The results of the acid resistance test are as follows Figure 1 As shown. Among them, all the coagulant Weizmannella VB320 died in 3 hours in simulated gastric fluid with a pH of 2.0, and died in 4 hours in simulated gastric fluid with a pH of 2.5. They can survive stably in simulated gastric fluid with a pH of 3 to 6 for 4 hours. The state of food affects its transit time in the stomach. Under normal circumstances, food stays in the stomach for 2 to 4 hours.

[0087] The results of the intestinal fluid resistance test are as follows Figure 2 Among them, the survival rate of Weizmannella coagulans VB320 in simulated intestinal fluid was about 98.28% for 2 hours and about 96.56% for 4 hours.

[0088] The results of the choline salt tolerance test are as follows Figure 3As shown, when the choline content was 0.033%-0.33%, the survival rate of Weizmannella coagulans VB320 was greater than 90% after 5 hours, indicating that the bacteria were stable in pancreatic juice within 5 hours. The above experimental results show that Weizmannella coagulans VB320 can survive in large quantities in the stomach, intestines, and pancreas, and can survive in areas susceptible to Helicobacter pylori infection.

[0089] Example 3 Helicobacter pylori inhibition test of coagulated Weizmannella

[0090] (1) Preparation of activated Helicobacter pylori suspension:

[0091] Helicobacter pylori Sydney strain SS1 was inoculated on a 90 mm Columbia blood agar plate (purchased from Huankai Biotechnology, product number CP0160) and cultured in an anaerobic environment for 72 to 96 h. After the culture, the Helicobacter pylori cells were collected, washed twice with PBS buffer, and 37 g of powdered BHI medium (purchased from BD, product number 237500) was dissolved in 1 L of distilled water, mixed and dispensed into the final container, and sterilized at 121°C for 15 minutes. The cells were resuspended with the prepared BHI medium and the concentration was adjusted to 1×10 7 CFU / mL, and obtain Helicobacter pylori suspension.

[0092] (2) Preparation of coagulated Weizmannella fermentation broth:

[0093] The Weizmannella coagulans VB320 separated in Example 1 was cultured in MRS liquid culture medium for 24 to 48 hours, and then the fermentation liquid was collected to obtain the Weizmannella coagulans VB320 fermentation liquid.

[0094] (3) Inhibition of Helicobacter pylori by strains

[0095] The activated Helicobacter pylori was inoculated into BHI liquid culture medium containing 5% fetal bovine serum and cultured at 37°C, 5% oxygen concentration and 10% carbon dioxide concentration until the microbial concentration reached 10 7 -10 8 CFU / mL. Then 0.1 mL of Helicobacter pylori culture fluid was evenly spread on Columbia blood agar plate to prepare a plate culture medium specifically for detecting Helicobacter pylori.

[0096] 2 μL of the fermentation supernatant of Weizmannella coagulans VB320 prepared in experiment (2) (the control group was BHI liquid culture medium) was inoculated into the above-mentioned Helicobacter pylori culture medium using a pipette tip, and cultured anaerobically at 37°C for 2 to 3 days. The size of the inhibition zone was then measured with a vernier caliper, which was the inhibitory effect of the strain on Helicobacter pylori. The test results are shown in Table 1. Weizmannella coagulans has an inhibitory effect on Helicobacter pylori.

[0097] Table 1. Inhibitory effect of Weizmannella coagulans on Helicobacter pylori

[0098]

[0099] Example 4 Testing of the Tolerance of Weizmannella coagulans to Antibiotics

[0100] The coagulant Weizmannella isolated in Example 1 was streaked onto an MRS agar plate and cultured at 37°C for 48 h to obtain a single colony. A single colony was selected and added to PBS to prepare a bacterial suspension, and the concentration of the bacterial suspension was adjusted to 10 8 CFU / mL. Take 350 μL of the prepared bacterial suspension and evenly apply it on the entire MRS solid plate with a sterile cotton swab. Place antibiotic susceptibility test strips (purchased from Hangzhou Microbiology) on the surface of the plate in an orderly manner at a certain distance. After incubation at 37°C for 48 hours, observe and measure the diameter of the inhibition zone with a vernier caliper. The results are shown in Table 2. The 20 common antibiotics have an inhibitory effect on the bacteria, and Weizmannella coagulans VB320 is a safe strain.

[0101] Table 2. Inhibitory effects of different antibiotics on Weizmannella coagulans VB320

[0102]

[0103] Example 5 Inhibitory effect of coagulated Wiesmann's on pathogenic bacteria

[0104] This example uses a double-layer plate culture method to test the antibacterial ability of the strain, and evaluates whether the coagulant Weizmannella VB320 has antibacterial ability based on the growth of pathogenic bacteria in the upper layer. The specific method is as follows:

[0105] The activated strain VB320 was thawed and inoculated in MRS separation medium at a bacterial inoculation volume of 2 μL / point, and then anaerobically cultured at 37°C for 4-5 days. Different pathogenic bacteria (Escherichia coli, Listeria monocytogenes, Enterococcus faecalis, Staphylococcus aureus, Salmonella, Shigella, and Capsula perfringens) were added to the sterilized upper culture medium cooled to 40°C-50°C and mixed. The final concentration of pathogenic bacteria in the culture medium was about 10 6 CFU / mL. The culture medium containing pathogenic bacteria was added to the above-mentioned grown strain VB320 plate at 7 mL / dish. After solidification, the culture was carried out according to the growth conditions of each pathogenic bacteria, and the size of the inhibition zone around the VB320 single colony was observed. The results are shown in Table 3. The coagulated Weizmannella VB320 had a certain inhibitory effect on the detected pathogenic bacteria.

[0106] Table 3. Evaluation of the antibacterial ability of Weizmannella coagulans VB320 against pathogenic bacteria

[0107]

[0108] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "embodiment" or "specific embodiment" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment are included in at least one embodiment of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments and features of the different embodiments described in this specification without contradiction.

[0109] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A coagulant Weizmannella VB320, It is characterized in that The coagulant Weizmannella VB320 was deposited in the China Center for Type Culture Collection on April 3, 2024, with the deposit number being CCTCC No: M 2024626.

2. The coagulant Weizmannella VB320 according to claim 1, It is characterized in that The Weizmannella coagulans VB320 has a 16S rRNA sequence as shown in SEQ ID NO:

1.

3. A fermentation liquid, It is characterized in that The fermentation broth is obtained by fermenting the Weizmannella coagulans VB320 according to claim 1 or 2, and the fermentation broth contains the Weizmannella coagulans VB320.

4. A bacterial suspension, It is characterized in that The bacterial suspension comprises the Weizmannella coagulans VB320 according to claim 1 or 2.

5. Use of the Weizmannella coagulans VB320 according to claim 1 or 2, the fermentation liquid according to claim 3 or the bacterial suspension according to claim 4 in the preparation of medicines or feeds for inhibiting the activity of pathogenic bacteria, in, The pathogenic bacteria include at least one of Helicobacter pylori, Listeria monocytogenes, Enterococcus faecalis, Staphylococcus aureus, Salmonella, Shigella and Capsula perfringens.

6. A composition, It is characterized in that The composition comprises at least one of the Weizmannella coagulans VB320 according to claim 1 or 2, the fermentation broth according to claim 3, and the bacterial suspension according to claim 4.

7. The composition according to claim 6, It is characterized in that The composition also includes an excipient.

8. The composition according to claim 7, It is characterized in that The excipient comprises at least one selected from a binder, a disintegrant, a lubricant, a glidant, a stabilizer and a filler.

9. The composition according to claim 6, It is characterized in that The composition also includes a carrier.

10. The composition according to claim 9, It is characterized in that The carrier comprises at least one selected from sugars, calcium phosphates, stearic acid alkaline earth metal salts, vegetable oils, nonionic surfactants, cationic surfactants, anionic surfactants, fatty alcohols and cereal hydrolyzed solids.

11. The composition according to claim 9, It is characterized in that The carrier includes cellulose.

12. The composition according to claim 6, It is characterized in that The dosage form of the composition includes at least one selected from oral liquid, powder, granule, capsule, tablet, and pill.

13. A method for inhibiting the growth of pathogenic bacteria in vitro, It is characterized in that include: At least one of the Weizmannella coagulans VB320 according to claim 1 or 2, the fermentation broth according to claim 3, and the bacterial suspension according to claim 4 is co-cultured with pathogenic bacteria, wherein the pathogenic bacteria include at least one of Helicobacter pylori, Listeria monocytogenes, Enterococcus faecalis, Staphylococcus aureus, Salmonella, Shigella, and Capsella perfringens.